The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Update concerning Guillain-Barré syndrome (GBS) following the administration of respiratory syncytial virus (RSV ...
MONTREAL — An investigational targeted immunotherapy for Guillain-Barré syndrome (GBS) more than doubled improvement in disability after 8 weeks compared with placebo and showed sustained benefit at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback